This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Roche Diabetes Care, Inc.. Active years: 2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018
Title: The Innovations of Marco Bocola in Glucose Oxidase Research
Introduction
Marco Bocola is a prominent inventor based in Aachen, Germany, known for his contributions to the field of biochemistry, particularly in the development of glucose oxidase variants. With a focus on improving blood glucose measurement techniques, Bocola has made significant strides that are beneficial for diabetes management.
Latest Patents
One of Bocola's key inventions is a patent for novel glucose oxidase (GOx) variants, identified for their unique amino acid substitutions. His patent details substitutions at positions T30V and I94V, as well as additional modifications in the amino acid sequence at select positions such as S53, A137, A173, A332, F414, and V560. These GOx variants demonstrate specificity for glucose while exhibiting reduced oxygen consumption rates, along with enhanced activity for alternative electron mediators. His innovation is not only groundbreaking in its chemical engineering aspect but also in the practical application via assay devices designed for improved blood glucose measurement.
Career Highlights
Marco Bocola currently works with Roche Diabetes Care, Inc., where he leverages his expertise in enzymology and biotechnology to develop solutions that can assist individuals living with diabetes. His focus on glucose oxidase research significantly enhances the accuracy and efficiency of blood glucose monitoring technologies.
Collaborations
Throughout his career, Bocola has collaborated with esteemed colleagues such as Hartmut Duefel and Erik Uwe Arango Gutierrez. Their combined efforts showcase a collaborative spirit that fosters innovation and leads to advancements in diabetes care technologies.
Conclusion
In summary, Marco Bocola's innovation in glucose oxidase variants stands as a testament to the impact that targeted research can have on healthcare. His work at Roche Diabetes Care, Inc. highlights a commitment to improving the lives of those affected by diabetes through advanced technological solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile